Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Recruiting

Phase 3

AZD6738 vs. DurvalumabTesting the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06732401

Conditions

Lung Non-Small Cell Carcinoma

Stage II Lung Cancer AJCC v8

Stage IIIA Lung Cancer AJCC v8

Stage IIIB Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Ceralasertib

Computed Tomography

Durvalumab

Echocardiography Test

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-14. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-09-05.